Targeted mass spectrometry for monitoring of neural differentiation.
Cell line characterization
Mass spectrometry
Neural differentiation
Neural stem cell
Protein marker
Selected reaction monitoring
Journal
Biology open
ISSN: 2046-6390
Titre abrégé: Biol Open
Pays: England
ID NLM: 101578018
Informations de publication
Date de publication:
15 08 2021
15 08 2021
Historique:
received:
26
03
2021
accepted:
28
06
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
22
3
2022
Statut:
ppublish
Résumé
Human multipotent neural stem cells could effectively be used for the treatment of a variety of neurological disorders. However, a defining signature of neural stem cell lines that would be expandable, non-tumorigenic, and differentiate into desirable neuronal/glial phenotype after in vivo grafting is not yet defined. Employing a mass spectrometry approach, based on selected reaction monitoring, we tested a panel of well-described culture conditions, and measured levels of protein markers routinely used to probe neural differentiation, i.e. POU5F1 (OCT4), SOX2, NES, DCX, TUBB3, MAP2, S100B, GFAP, GALC, and OLIG1. Our multiplexed assay enabled us to simultaneously identify the presence of pluripotent, multipotent, and lineage-committed neural cells, thus representing a powerful tool to optimize novel and highly specific propagation and differentiation protocols. The multiplexing capacity of this method permits the addition of other newly identified cell type-specific markers to further increase the specificity and quantitative accuracy in detecting targeted cell populations. Such an expandable assay may gain the advantage over traditional antibody-based assays, and represents a method of choice for quality control of neural stem cell lines intended for clinical use.
Identifiants
pubmed: 34357391
pii: 271174
doi: 10.1242/bio.058727
pmc: PMC8353267
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021. Published by The Company of Biologists Ltd.
Déclaration de conflit d'intérêts
Competing interests The authors declare no competing or financial interests.
Références
Nat Biotechnol. 1998 Nov;16(11):1033-9
pubmed: 9831031
Nat Methods. 2014 Oct;11(10):1045-8
pubmed: 25194849
Mol Cell Proteomics. 2014 Jan;13(1):311-28
pubmed: 24173317
Bioinformatics. 2014 Sep 1;30(17):2524-6
pubmed: 24794931
Nature. 2003 Mar 13;422(6928):198-207
pubmed: 12634793
Mol Syst Biol. 2008;4:222
pubmed: 18854821
Mol Cell Proteomics. 2016 Feb;15(2):344-54
pubmed: 26494823
Neuron. 2014 Aug 20;83(4):789-96
pubmed: 25123310
Cell Transplant. 2010;19(9):1103-22
pubmed: 20412634
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Biotechnol. 2007 Jul;25(7):803-16
pubmed: 17572666
Exp Neurol. 1997 Nov;148(1):135-46
pubmed: 9398456
Prog Neurobiol. 2013 Nov;110:63-73
pubmed: 23665410
Cell Syst. 2016 Apr 27;2(4):225-38
pubmed: 27135535
Cell. 2012 Sep 14;150(6):1264-73
pubmed: 22980985
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):829-32
pubmed: 24379375
J Neurosci Res. 2005 May 15;80(4):456-66
pubmed: 15795928
J Stroke Cerebrovasc Dis. 2013 May;22(4):304-8
pubmed: 22078778
Opera Med Physiol. 2016 Dec;2(3-4):181-187
pubmed: 28795171
Proteomics. 2015 Feb;15(4):656-74
pubmed: 25418965
Stem Cell Res Ther. 2013 May 28;4(3):57
pubmed: 23710605
Nat Biotechnol. 2007 Dec;25(12):1468-75
pubmed: 18037878
Trends Neurosci. 1991 Aug;14(8):338-40
pubmed: 1721737
Proteomics Clin Appl. 2015 Aug;9(7-8):684-94
pubmed: 25684324
Acta Neuropathol Commun. 2019 Jun 3;7(1):84
pubmed: 31159890
Int J Mol Sci. 2017 Dec 13;18(12):
pubmed: 29236046
Eur J Histochem. 2016 Feb 01;60(1):2563
pubmed: 26972711
J Proteomics. 2016 Jan 30;132:13-20
pubmed: 26581640
Nat Biotechnol. 2001 Dec;19(12):1129-33
pubmed: 11731781
Front Cell Neurosci. 2015 Mar 18;9:87
pubmed: 25852479
Mol Cell Proteomics. 2012 Apr;11(4):M111.014662
pubmed: 22190732
Stem Cell Res Ther. 2013 Jun 14;4(3):73
pubmed: 23769173
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11839-44
pubmed: 15280535
Expert Rev Proteomics. 2015 Feb;12(1):83-95
pubmed: 25363140
PLoS One. 2011 Mar 02;6(3):e17540
pubmed: 21407814
PLoS One. 2012;7(12):e52787
pubmed: 23300777
Stereotact Funct Neurosurg. 2010;88(1):56-63
pubmed: 20051711
Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79
pubmed: 21896369
PLoS One. 2012;7(8):e42614
pubmed: 22916141
Exp Neurol. 1999 Aug;158(2):265-78
pubmed: 10415135
Sci Data. 2019 Feb 19;6:190016
pubmed: 30778261
Front Cell Neurosci. 2021 Jan 28;14:612560
pubmed: 33584205
Genes Cells. 2019 Dec;24(12):836-847
pubmed: 31651061
Cell. 1999 Jan 8;96(1):25-34
pubmed: 9989494
Neuroscience. 2007 Jun 29;147(2):546-60
pubmed: 17524565
Stem Cell Res Ther. 2019 Mar 12;10(1):83
pubmed: 30867054
Nat Med. 1998 Nov;4(11):1313-7
pubmed: 9809557
Bioinformatics. 2010 Apr 1;26(7):966-8
pubmed: 20147306
Exp Neurol. 1999 Mar;156(1):71-83
pubmed: 10192778
Mol Cell Proteomics. 2008 Apr;7(4):750-67
pubmed: 18304949
Cell. 1999 Jun 11;97(6):703-16
pubmed: 10380923
Nat Rev Neurosci. 2010 Mar;11(3):176-87
pubmed: 20107441
Cell. 2014 Feb 27;156(5):1072-83
pubmed: 24561062
Hum Gene Ther. 2005 Apr;16(4):509-21
pubmed: 15871682